Panel Of Former US FDA Commissioners Make Renewed Call For Independent Agency
Former FDA heads reflected on instances when they experienced pressure from their higher-ups; speakers also offered praise for the job Commissioner Scott Gottlieb is doing at the agency.
You may also be interested in...
Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.
In an interview with the Pink Sheet, Scott Gottlieb agrees with other ex-commissioners that there are benefits to an independent agency, but he thinks political forces would prevent it from ever happening.
Recent draft guidance documents address adolescent enrollment in adult cancer trials, use of cohort designs in early-phase studies, and inclusion of placebo controls; more advice is coming soon on master protocols, adaptive designs and novel endpoints, FDA's Gottlieb says.